A polypeptide composition with lipid-lowering effect and its application

By coupling polypeptide compositions with 6-segment peptide epitope to immune carrier proteins in heat shock proteins, the side effects of existing blood lipid-lowering drugs and the difficulty in maintaining weight loss for a long time are solved, and significant blood lipid regulation and Lowering sugar effect and no side effects.

CN117582488BActive Publication Date: 2024-11-19INST OF ZOOLOGY GUANGDONG ACAD OF SCI
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202311558509.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-22
Publication Date
2024-11-19
Estimated Expiration
2043-11-22

AI Technical Summary

Technical Problem

Existing lipid-lowering drugs have side effects and are difficult to maintain weight loss for a long time. The existing lipid-lowering polypeptides focus mainly on nutritional value and do not take advantage of their potential in the field of immunomodulation.

Method used

A polypeptide composition based on the 6-segment peptide epitope of the heat shock protein and the keyhole hemocyanin coupling of the protein protein keyhole hemocyanin is delivered through the nasal drop mucosa to regulate the immune response to achieve a lipid-lowering effect.

Benefits of technology

It significantly reduces the triglyceride and low-density lipoprotein cholesterol levels in cynomolgus monkeys, regulates blood lipid metabolism, and has no obvious side effects. It has a sugar-lowering effect, is easy to use and is easy to accept by patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117582488B_ABST
    Figure CN117582488B_ABST
Patent Text Reader

Abstract

The present invention discloses a polypeptide composition with lipid-lowering effect and its application, and relates to the field of biopharmaceutical technology. The polypeptide composition H-6X is composed of 6 peptide epitopes based on heat shock protein, which are coupled with the immune carrier protein-keyhole limpet hemocyanin and then mixed. The polypeptide composition of the present invention has a good effect of reducing triglycerides and low-density lipoprotein cholesterol at the same time, and no obvious toxic and side effects were found in the study. In addition, the medication is convenient, the utilization rate is high, and it is easily accepted by patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biopharmaceutical technology, and more particularly to a polypeptide composition with lipid-lowering effect and its application. Background Art

[0002] At present, there are about 1.9 billion overweight adults in the world, of which more than 600 million are obese. When lifestyle intervention is ineffective, that is, it cannot reduce body weight by 5%, and the BMI index is still greater than 28, drug treatment is recommended; patients who are overweight and have a complication (cardiovascular disease, hypertension, type 2 diabetes, etc.) are also recommended to receive drug treatment if lifestyle intervention is ineffective. There are more than 1 billion patients in the world who need drug treatment. Changing lifestyle is the main method of obesity treatment. It is difficult to maintain long-term weight loss by relying solely on diet control. Although many methods of treating obesity have been developed, most of them have toxic side effects and adverse reactions.

[0003] Common lipid-lowering drugs in the prior art include statins, a type of cholesterol biosynthesis enzyme inhibitor, which is currently the most widely used type of lipid-lowering drug in clinical practice and the main drug for treating hypercholesterolemia. This type of drug has gastrointestinal reactions and headaches, and may cause muscle toxicity when used in combination with other lipid-lowering drugs. Other lipid-lowering drugs include fibrates, which are mainly used for hypertriglyceridemia or mixed hyperlipidemia with elevated triglycerides as the main cause. Common adverse reactions of this drug are gastrointestinal reactions, nausea, diarrhea, and severe cases can cause liver damage.

[0004] The prior art also discloses lipid-lowering polypeptides, such as albumin, α1-globulin, α2-globulin, β-globulin and γ-globulin, which are rich in camel blood. Due to the special living environment, the proteins in its blood have a unique chemical structure and exhibit unique physiological activity, which can maintain the constancy of plasma colloidal osmotic pressure and transport function, etc. However, most of the lipid-lowering polypeptides in the prior art focus on their nutritional value, and do not pay attention to their application in the field of immune regulation.

[0005] Therefore, the present application provides a polypeptide composition that utilizes mucosal immunity to achieve lipid-lowering effects, expanding new applications of polypeptide compositions in the direction of lipid-lowering. Summary of the invention

[0006] In view of this, the present invention provides a polypeptide composition with lipid-lowering effect and its application.

[0007] In order to achieve the above object, the present invention adopts the following technical solution:

[0008] A polypeptide composition with lipid-lowering effect, wherein the polypeptide composition H-6X is composed of 6 peptide epitopes based on heat shock protein (HSP) respectively coupled with an immune carrier protein - keyhole limpethemoeyanin (KLH) and then mixed.

[0009] Furthermore, the six peptide epitopes are:

[0010] CV14, the amino acid sequence is shown in SEQ ID NO: 1;

[0011] CL14, the amino acid sequence is shown in SEQ ID NO: 2;

[0012] CE19, the amino acid sequence is shown in SEQ ID NO: 3;

[0013] CD17, the amino acid sequence is shown in SEQ ID NO: 4;

[0014] CQ19, the amino acid sequence is shown in SEQ ID NO: 5;

[0015] CL26, the amino acid sequence is shown in SEQ ID NO:6.

[0016] Furthermore, the method for coupling the peptide epitope with the immune carrier protein-keyhole limpet hemocyanin comprises the following steps:

[0017] 1) Activating the immune carrier protein, keyhole limpet hemocyanin, with SMCC cross-linking agent and dialyzing for 24 hours for later use;

[0018] 2) coupling the immune carrier protein-keyhole limpet hemocyanin with the peptide epitope at a mass ratio of 1:1 for 2 hours;

[0019] 3) The coupled product was dialyzed for 24 hours for later use.

[0020] Furthermore, the mixing is uniform mixing.

[0021] A pharmaceutically acceptable composition comprises the polypeptide composition and one or more pharmaceutically acceptable excipients.

[0022] Furthermore, the composition is formulated to be delivered via intranasal mucosal immunization.

[0023] A use of a polypeptide composition with lipid-lowering effect in the preparation of a lipid-lowering drug.

[0024] It can be seen from the above technical solution that, compared with the prior art, the beneficial effects of the present invention are:

[0025] The polypeptide composition of the present invention has no significant effect on the growth of cynomolgus monkeys after immunization, and has no significant side effects on normal growth in terms of behavior and body size.

[0026] Immunotherapy with the H-6X epitope composition can significantly reduce the serum TG and LDL-C levels of crab-eating macaques, and the TC level has been lower than that of the control group in the later period, which can achieve the effect of regulating blood lipid metabolism disorders.

[0027] The present invention also tested blood sugar. Although a single comparison did not show a significant difference, after immunization with the H-6X polypeptide composition, the blood sugar level of the immunized group was lower than that of the control group in the later stage of the experiment, indicating that it also had a certain blood sugar-lowering effect.

[0028] The polypeptide composition of the present invention has a good effect of reducing triglycerides and low-density lipoprotein cholesterol, and no obvious toxic side effects were found in the study. In addition, the medication is convenient, the utilization rate is high, and it is easily accepted by patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0030] Figure 1 This is a weight change trend chart;

[0031] Figure 2 This is a BMI change trend chart;

[0032] Figure 3 This is a graph showing changes in TG levels in cynomolgus monkey serum;

[0033] Figure 4 This is a graph showing changes in LDL-C levels in cynomolgus monkey serum;

[0034] Figure 5 This is a graph showing changes in TC levels in cynomolgus monkey serum;

[0035] Figure 6 This is a graph showing changes in GLU content in cynomolgus monkey serum;

[0036] Figure 7 This is a graph showing the changing trend of anti-Hsp65 IgG antibodies in the serum of cynomolgus monkeys after nasal mucosal immunization;

[0037] Figure 8 This is a graph showing the changing trend of anti-CV14 IgG antibodies in the serum of cynomolgus monkeys after nasal mucosal immunization;

[0038] Fig. 9 This is a graph showing the changing trend of anti-CV14 IgG antibodies in the serum of cynomolgus monkeys after nasal mucosal immunization;

[0039] Fig.10 This is a graph showing the changing trend of anti-CL26 IgG antibodies in the serum of cynomolgus monkeys after nasal mucosal immunization;

[0040] Fig.11 This is a graph showing the changing trend of anti-CD17 IgG antibodies in the serum of cynomolgus monkeys after nasal mucosal immunization;

[0041] Fig.12 This is a graph showing the changing trend of anti-CE19 IgG antibodies in the serum of cynomolgus monkeys after nasal mucosal immunization;

[0042] Fig.13 This is a graph showing the changing trend of anti-CQ19 IgG antibodies in the serum of cynomolgus monkeys after nasal mucosal immunization;

[0043] Fig.14 This is a graph showing the difference in expression of serum IL-4 in cynomolgus monkeys;

[0044] Fig.15 This is a graph showing the difference in expression of serum IL-10 in cynomolgus monkeys;

[0045] Fig.16 This is a graph showing the difference in expression of TNF-α in cynomolgus monkey serum;

[0046] Fig.17 This is a graph showing the difference in expression of IFN-γ in the serum of cynomolgus monkeys. DETAILED DESCRIPTION

[0047] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0048] Example 1

[0049] Research on lipid-regulating effects:

[0050] Selection of experimental animals: 30 cynomolgus monkeys about 7 years old (purchased from Guangdong Landao Biotechnology Co., Ltd.) were selected and raised in single cages (specifications: 70 cm × 70 cm × 80 cm), one monkey per cage, and the temperature in the breeding room was 18-26°C and the relative humidity was 60%-80%. Conventional feed was used in the early stage, and the monkeys' daily diet was observed every other day. The necessary blood and biochemical tests were performed before the diet-induced model was induced. Monkeys with tuberculosis and immunodeficiency (SIV and STIV) were detected and excluded, and the monkeys with normal behavior and normal physiological and biochemical indicators, age and weight, and no defects were screened and finally determined for the diet-induced atherosclerosis model. They were divided into a polypeptide immunization group (high-fat diet induced-H-6X nasal immunization) and a control group (high-fat diet induced-PBS nasal immunization) and a blank control group (normal diet-Control) without any treatment.

[0051] Experimental agents: High-fat feed was prepared by Guangzhou Feed Research Institute according to the formula and stored in a low-temperature cold storage with a shelf life of 2 weeks. The 6-segment HSP65 epitope peptide for immunization was synthesized by Jier Biochemical (Shanghai) with a purity of ≥90%. Cholesterol came from Guangzhou Qiyun Biotechnology Co., Ltd. with a purity of ≥95%. Ketamine hydrochloride, an anesthetic drug, was produced by Shenyang Veterinary Medicine Factory. All other unspecified experimental materials were common commercially available types.

[0052] Collection of blood samples from cynomolgus monkeys: The monkeys must fast overnight before blood collection. They are lightly anesthetized with ketamine hydrochloride (0.05 mg / kg). After 10 to 20 minutes of anesthesia, their body weight and sitting height are measured. Whole blood is collected from the hind limb vein, left at room temperature for 30 minutes, centrifuged at 4°C and 4000 r / min (Ependorf5810r) for 8 minutes, and the upper serum is taken and sent for testing at low temperature. The main blood biochemical indicators tested include triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), blood sugar (GLU), etc. All of them were obtained by Guangzhou KingMed Medical Testing Center. The instrument used is Roche P800, and all are Roche matching reagents and kits. The frequency of blood collection is about once every 1.5 months. The blood is collected once before high-fat diet induction (D0), and high-fat diet feeding of crab-eating macaques begins on the same day; the first test after high-fat induction is 2 months later (D60), and nasal drop immunization begins on the same day; subsequently, serum is collected and sent for testing multiple times every 1.5 months.

[0053] High-fat diet induction: A high-fat diet was used, with a feed formula of 15% lard + 1.5% cholesterol, and the rest was supplemented with monkey growth feed. Fifteen healthy male cynomolgus monkeys were selected and fed in a single cage, 10 of which were fed a high-fat diet, and the other 5 were fed a normal diet as a control group. The appearance, behavior, and daily diet of the cynomolgus monkeys were observed and recorded during the experiment.

[0054] Peptide synthesis: The six peptide sequences on HSP65 are:

[0055] ① LEDPYEKIGA ELV (CV14), as shown in SEQ ID NO: 1;

[0056] ②ATVLAQALVR EGL (CL14), as shown in SEQ ID NO: 2;

[0057] ③I AEAMDKVGNE GVITVEE (CE19), as shown in SEQ ID NO: 3;

[0058] ④DPFILL VSSKVSTVKD (CD17), as shown in SEQ ID NO: 4;

[0059] 5. EATGANIV RVALERPLKQ (CQ19), as shown in SEQ ID NO: 5;

[0060] ⑥AGI ADPVKVTRSA LQNAASI AGL FL (CL26), as shown in SEQ ID NO: 6;

[0061] In order to increase the immunogenicity of the polypeptide, keyhole limpet hemocyanin (KLH) with strong immunogenicity was selected as the immune carrier protein for coupling synthesis.

[0062] The solid phase synthesis purification method is used to prepare the polypeptide, comprising the following steps:

[0063] (1) According to the specific starting amino acid type of synthetic peptide, select and weigh the corresponding resin. The peptide sequence synthesis adopts the reverse synthesis method from C-terminus to N-terminus. First, Fmoc-the first amino acid -OH is placed in a glass reaction column and swelled with dichloromethane (DCM) for 30 minutes, and the DCM is removed under reduced pressure;

[0064] (2) Wash the resin with dimethylformamide (DMF) three times, add 20% piperidine / DMF solution to react for 20 min to remove the protective group fmoc, remove the solution under reduced pressure, and wash with DMF six times;

[0065] (3) Weigh the second amino acid Fmoc-second amino acid-OH and condensing agent TBTU separately, add them to the resin, dissolve in DMF and add diisopropylethylamine (DIEA); react for 30 minutes, take the resin for color test reaction, observe the color of the solution and the resin, the solution is bright yellow and the resin is yellow, indicating that the reaction is complete.

[0066] Remove the solvent under reduced pressure;

[0067] (4) Repeat steps (2) and (3) until the last amino acid Fmoc-the last amino acid Cys(Trt)-OH is connected, react for 1 hour, then wash with DMF, DCM, and methanol three times each, and drain the resin;

[0068] (5) Add lysis solution to remove the resin and amino acid side chain protecting groups, filter through a sand core, add ether to the filtrate to precipitate, centrifuge, wash the solid three times, drain, and send to ESI-MS for detection. The purity is above 95% and the product is qualified.

[0069] After obtaining the above peptide with Cys at the N-terminus, it is coupled with KLH. The coupling process is as follows:

[0070] 1) KLH was activated with SMCC cross-linker and dialyzed for 24 hours;

[0071] 2) KLH and peptide were reacted at a mass ratio of 1:1 for 2 h;

[0072] 3) After coupling, the product is dialyzed for 24 hours.

[0073] Immunization method: 6 peptides were mixed in equal amounts (H-6X), and small doses of multiple nasal drops were used for immunization. Considering the loss during the immunization process, the immunization dose of each cynomolgus monkey was 800ul / monkey each time. When the cholesterol concentration of the blood biochemical index was significantly higher than that of the control group (D60), small doses of nasal drops were started, for a total of 15 times of nasal drops, and immunization was given every other day. The first 10 times of immunization were continued every other day, and the administration was stopped after 10 times; the immunization was strengthened half a month later, and the next 5 times of immunization were continued every other day.

[0074] Physical changes of cynomolgus monkeys: During the experiment, the appearance, behavior, activities, food intake, feces, and the condition of the eyes, ears, skin and other organs of the cynomolgus monkeys were observed with the naked eye. During each blood draw, their weight, sitting height, waist circumference and sitting waist circumference were measured at the same time.

[0075] Data processing method: All data in the article were analyzed statistically using Excel software. Statistical analysis was performed using Student's t test. All data measured in the experiment were expressed in the form of ±s. P<0.01 indicated a very significant difference, and P<0.05 indicated a significant difference.

[0076] Changes in signs of cynomolgus monkeys (see Figure 1 ): During the experiment, the appearance, behavior, activities, food intake, weight, feces, eyes, ears, skin and other organs of the experimental monkeys were observed with the naked eye. No abnormal changes were found. The weight changes were normal and increased day by day.

[0077] Therefore, it can be seen from the appearance and physical signs alone that the polypeptide combination has no obvious effect on the growth of crab-eating macaques after immunization, and has no obvious side effects on normal growth in terms of behavior and body size.

[0078] From daily observation of physical signs and determination of body weight and BMI (see Figure 2 ), it can be seen that during the whole process, the body weight of the immunized group showed an overall upward trend compared with the PBS immunized high-fat control group and the blank control group, and there were no obvious side effects of polypeptide immunization. Overall, the body weight and BMI of the high-fat diet group were lower than those of the blank control group. This is because the crab-eating macaques selected were middle-aged crab-eating macaques, and their height would not change much. However, under the condition of single-cage feeding, there were fewer animals and their body weight would continue to increase. However, since crab-eating macaques may not be able to adapt to the taste of high-fat feed, their food intake will be correspondingly lower than that of the blank control group, so it is expected that their overall body weight after high-fat feeding will be slightly lower than that of the blank control group. However, since the food intake remained stable and the overall body weight also showed an upward trend, it was considered that no obvious side effects were caused to them.

[0079] Study on lipid-regulating effect (effect on TG, TC, LDL-C, HDL-C) and investigation on blood sugar lowering effect:

[0080] Since the blank control group did not change significantly during the entire experiment, the comparison with it was not significant, so it was not included in the statistics for comparison. Only the serum test results of the two groups of high-fat diet-induced crab-eating macaques (peptide combination and PBS immunization control group) were compared. Data 1-9 in the figure are the serum test results of the PBS control and nasal administration groups, 1 is before high-fat induction (D0), 2 is the first immunization started on the day of blood collection 2 months after high-fat induction (D60), and 3-9 are blood samples drawn every 35 days since 2 (D60).

[0081] Detection of serum TG levels in cynomolgus monkeys after immunization (see Figure 3 ): Compared with the PBS control group, the difference in serum TG content in the polypeptide immunization group was not obvious at the beginning of administration. As time went on, the difference increased. The fourth statistical analysis after immunization reached a very significant difference (P<0.01). From the fifth to the late stage of the animal experiment, there was a statistical difference (P<0.05), but the difference was not too significant afterwards. However, it can be seen that the TG content continued to be lower than that of the PBS immunization group in the last few tests. The results are shown in Table 1.

[0082] Table 1 Serum TG content (±SD) (n=5)

[0083]

[0084] Compared with PBS, *represents P<0.05, **represents P<0.01

[0085] The data in Table 1 show that in the fifth test (the third test after immunization), the average TG content of the H-6X immunization group was 0.1775±0.02mmol / L, while that of the PBS group was 0.298±0.06mmol / L. Compared with the PBS group, the TG content of the H-6X immunization group decreased by 41.27%, which was a very significant difference (P<0.01); in the sixth test, the average TG content of the H-6X immunization group was 0.224±0.06mmol / L, while that of the PBS group was 0.32±0.05mmol / L. Compared with the PBS group, the TG content of the administration group decreased by 30.0%, which was a significant difference (P<0.05). Although there was no significant difference in the subsequent tests, they were all lower than the PBS control group.

[0086] Serum LDL-C levels in cynomolgus monkeys after immunization (see Figure 4 ): Compared with the PBS control group, the H-6X polypeptide composition immunization group had no significant difference in serum LDL-C content at the beginning of administration. As time went on, the difference increased. The seventh test result (fifth time after immunization) reached a very significant difference (P<0.01). Although there was no statistical difference in the next two times, the LDL-C content of the H-6X group continued to be lower than that of the PBS immunization group and remained until the end of the experiment. The results are shown in Table 2.

[0087] Table 2 Serum LDL-C content (±SD) (n=5)

[0088]

[0089] Compared with PBS, *represents P<0.05

[0090] As can be seen from Table 2, when compared with the 7th test at the later stage of immunization, the LDL-C concentration in the H-6X immunization group was 1.136mmol / L, while that in the PBS group was 2.772mmol / L. Compared with the PBS group, the TG content in the drug administration group decreased by 59.02%, and the difference was significant (P<0.05).

[0091] Detection of serum TC content in cynomolgus monkeys after immunization (see Figure 5): The TC content was low before high-fat induction, but high-fat diet induction had begun in the second test. The TC content quickly rose to the highest level, and then gradually returned to a low level in the later period. It may be due to the body's energy regulation of high-fat diet after a period of time, and the source and destination of TC gradually reached a relatively balanced state. However, under the condition of continuous high-fat diet, it still maintained a TC level far higher than that of normal crab-eating monkeys. After a period of immunization and booster immunization, the TC content of the polypeptide immunization group was lower than that of the PBC immunization group until the end of the experiment. Although there was no statistically significant difference in the comparison of single tests. However, when the two groups of data for the last five tests were compared, there was an extremely significant difference between the two groups (P<0.01). Because the high-fat diet contains a certain amount of TC components in the feed components, and it has been continuously fed, the direct effect of reducing TC is not very significant, but considering this point, and considering the comprehensive test results, it has a certain effect on reducing TC levels.

[0092] Effects of immunization on blood glucose (GLU) levels in cynomolgus monkeys (see Figure 6 ): Because hyperglycemia is one of the four most important factors causing AS, the present invention also tested the fasting blood glucose content of cynomolgus monkeys. No significant difference was detected during the whole process. However, in the middle and late stages of immunization, from the 6th test to the end of the experiment, the GLU level of the H-6X polypeptide immunization group was always lower than that of the PBS immunization group. A comprehensive statistical analysis was performed on the test results of the 6th to 9th times, a total of 4 times in the late stage of the experiment after immunization, and the two groups showed significant differences (P<0.05). Like the TC level, the difference in the comparison of the single test results in the late stage of immunization did not reach a statistically significant difference, which may be related to the lack of immunogenicity of the immune polypeptide, which can be improved by transformation or improvement or by immune adjuvants to make the drug effect more obvious. A comprehensive analysis of the GLU data results showed that this B cell epitope peptide may also have a good hypoglycemic effect if its immunogenicity is improved by changing the immunization method or reconstructing or adding immune adjuvants.

[0093] Dyslipidemia is one of the most important causes of AS, among which TC, TG, and LDL-C are regarded as the hazard factors for AS, and are also important warning indicators for routine detection of AS and cardiovascular disease. Combined with the previous experience of high-fat diet-induced AS model in cynomolgus monkeys and the results of this experiment, the serum TG, TC, and LDL-C of cynomolgus monkeys fed with high-fat diets were significantly increased compared with the normal background values, indicating that the AS model was successfully established. After H-6X immunotherapy, the results showed that compared with the PBS control group, the H-6X immune group had significant or even extremely significant decreases in TG and LDL-C at different periods after immunization, and the TC content was always lower than that of the control group in the late stage of immunization. The difference in the level of decrease was also obvious when all the data were compared. As for the reason why the single test was not obvious, it may be because the high-fat diet was directly added with cholesterol to induce the reason, so it may take a longer time to observe the significant difference. Therefore, immunotherapy with the H-6X epitope composition can significantly reduce the serum TG and LDL-C levels of cynomolgus monkeys, and the TC level is always lower than that of the control group in the later stage, which can achieve the effect of regulating blood lipid metabolism disorders. The anti-AS effect of HDL-C has been confirmed, but the present invention failed to show a significant difference between the two groups, so it was not presented. However, the research results can show that H-6X has a prominent effect in reducing TG and LDL-C, and has a significant lipid-regulating effect on high-fat diet-induced AS in cynomolgus monkeys. As one of the four important causes of AS, high blood sugar is also tested in the present invention. Although a single comparison does not show a significant difference, after immunization with the H-6X polypeptide composition, the blood sugar value of the immunized group has been lower than that of the control group in the later stage of the experiment, indicating that it also has a certain hypoglycemic effect.

[0094] Example 2

[0095] Preliminary mechanism of lipid-lowering effect of peptide composition H-6X on cynomolgus monkeys:

[0096] Continuous hyperlipidemia can cause lipid deposition in the vascular endothelium. If not paid attention to for a long time, it will block the blood vessels and form emboli, which is easy to cause metabolic syndrome, including hypertension, diabetes, cardiovascular and cerebrovascular diseases such as cerebrovascular disease, atherosclerosis, etc., and atherosclerosis caused by hyperlipidemia is currently considered to be an inflammatory autoimmune disease. Immunological tolerance to autoantibodies mediated by specific antigens through mucosal administration is one of the more commonly used treatment methods for autoimmune diseases. Antibodies against HPS can be detected in patients with hyperlipidemia and atherosclerosis. The present invention adopts the method of mucosal immunity, and induces specific immune tolerance against autoantibodies such as HSP by multiple administrations of small doses to achieve the purpose of lipid reduction, lipid regulation, anti-inflammatory, and even anti-atherosclerotic plaques. Mucosal immunity can not only be used to prevent or treat autoimmune diseases, but also for diseases related to inflammation, inducing the inflammatory TH1 type immune response to shift to the anti-inflammatory TH2 type immune response, and achieving a near-normal Th1 / TH2 immune balance.

[0097] The first is the detection of anti-HSP65 and anti-6-segment polypeptide (CV-14, CL-14, CE-19, CD-117, CQ-19, CL-26) IgG antibodies; the second is the expression changes of important related inflammatory cytokines (IL10, IL4, TNF-α and IFN-γ, etc.) throughout the process and their role in the immune process.

[0098] Detection of IgG antibodies against HSP65 macromolecular proteins and peptides:

[0099] Test reagents: coating antigen HSP65, experimental protein extraction; polypeptide coating antigen synthesized by Gill Biochemical (Shanghai); goat anti-monkey IgG labeled with horseradish peroxidase (Southern Biotechnology Associates, Inc., SBA); the rest are conventional reagents, domestic AR grade, purchased from different domestic biotechnology and biochemical reagent companies.

[0100] Detection of anti-IgG antibodies: The specific experimental steps are as follows: ① According to the results of the preliminary experiment, dilute the antigen to a concentration of 1ng / ul with the coating solution. ② Add the antigen to the ELISA plate, 100ul per well, and coat overnight at 4℃. ③ Rinse the ELISA plate with PBST, repeat 3 times, and spin dry the PBST in the ELISA plate for the last time. ④ Add 200ul of blocking solution to each well, incubate in a 37℃ incubator for 2h, and repeat step 3 after the end. ⑤ Dilute the serum 1:100 with PBS, add 100ul of diluted serum to each well, incubate in a 37℃ incubator for 1h, and repeat step 3. ⑥ Dilute the secondary antibody 1:5000 with PBS, add 100ul of diluted secondary antibody to each well, incubate in a 37℃ incubator for 1h, and repeat step 3. ⑦ Add 100ul of TMB single-component colorimetric solution to each well, and color at room temperature for 10min under dark conditions. ⑧ Add stop solution (2M H2SO4) to terminate the reaction, 50ul per well, and measure the OD value of each well with an ELISA reader (λ=450).

[0101] ELISA test for antibody production: HSP65 protein and peptides CV14, CL14, CE19, CQ19, CD17 and CL26 were used as coating antigens to detect the production of specific antibodies in the serum of the high-fat diet control group and the immune group immunized with PBS. The test results are as follows ( Figure 7-Figure 13 ).

[0102] Detection of anti-HSP65 IgG antibodies in cynomolgus monkey serum (see Figure 7 ): HSP65 was used as the coating antigen, from the bottom Figure 7 It can be seen that there is no significant statistical significance, but in the early stage of administration, the titer of anti-HSP65 IgG antibody in H-6X was significantly different from that in the PBS control group. As time went on, the difference was not obvious. This is consistent with the test results of anti-HSP65 IgG antibody. It may be related to the adaptation of the body to external stimulation caused by the initial high-fat diet.

[0103] Using HSP65 as the coating antigen, the experimental results showed no statistical significance compared with the PBS group, but at the beginning of administration, the anti-HSP65 IgG titer of the H-6X group was slightly higher than that of the PBS control group. Figure 7It can be seen that the PBS group also produced very low titers of antibodies, and the antibody value against HSP65 was not zero. This may be due to the infection of external microorganisms caused by the breeding environment, which caused the body to produce anti-HSP65 antibodies. H-6X produced slightly higher antibodies than the PBS group in the early stage, although the difference was not obvious, indicating that in the initial nasal mucosal administration, due to the frequent and large-scale contact of the body with the stimulation of the H-6X immunogen, a certain immune response occurred, and antibodies against HSP65 were produced. As time went on, there was no difference from the PBS control group; in addition, it may be that after the initial low-dose multiple immunizations with the combined polypeptide antigen, T cells may have been suppressed, but due to the toxicity of the antibody itself, the body produced low-titer antibodies.

[0104] Detection of specific anti-IgG antibodies against 6 epitope peptides in cynomolgus monkey serum: IgG antibodies against specific epitope peptides were detected using the 6 epitope peptides CV14, CL14, CE19, CQ19, CD17 and CL26 as coating antigens.

[0105] The production of antibodies against the CV14 epitope in the sera of the immunized group was detected by using the CV14 synthetic peptide among the 6 epitopes as the coating antigen. There was no significant difference compared with the PBS control group. The results are shown in Figure 8 .

[0106] The production of antibodies against the CL14 epitope in the sera of the immunized group was detected using the CL14 synthetic peptide as the coating antigen. There was no significant difference compared with the PBS control group. Fig. 9 .

[0107] The CL26 synthetic peptide was used as the coating antigen to detect the production of antibodies against the CL26 epitope in the sera of the immunized group. There was no significant difference compared with the PBS control group. The results are shown in Fig.10 Although there is no statistically significant difference, the production of antibodies to this epitope is significantly different from the results of several other epitopes. From the figure, it can be seen that the PBS group is always the same as the other two groups. Further investigation and analysis is needed.

[0108] The CD17 synthetic peptide was used as the coating antigen to detect the production of antibodies against the CD17 epitope in the sera of the immunized group. There was no significant difference compared with the PBS control group. The results are shown in Fig.11 .

[0109] The production of antibodies against the CE19 epitope in the immunized group serum was detected using CE19 synthetic peptide as the coating antigen. There was no significant difference compared with the PBS control group. Fig.12 .

[0110] The CQ19 synthetic peptide was used as the coating antigen to detect the production of antibodies against the CQ19 epitope in the sera of the immunized group. There was no significant difference compared with the PBS control group. The results are shown in Fig.13 .

[0111] The present invention uses 6-segment synthetic peptides as coating antigens, and compared with PBS, there is no significant difference in statistical analysis. This is likely to indicate that the body has developed tolerance to HSP65. Whether the specific T cells are suppressed as speculated requires further experiments to support and verify. In addition, a careful analysis of the expression of IgG antibodies against the H-6X combination polypeptides above revealed some rules and some differences. In future work, based on these rules and differences, a certain epitope can be connected in series multiple times alone, or epitopes with consistent rules can be connected in series to enhance immunogenicity, and more effective lipid-regulating epitope peptides can be screened after immunizing animals.

[0112] After H-6X immunization, whether TH1 to TH2 cell drift occurs in the body, the present invention further analyzes cytokines such as TH2 anti-inflammatory cytokines IL-4, IL-10 and TH1 inflammatory cytokines TNF-α, IFN-γ and other inflammation-related cytokines, and analyzes the production of various inflammatory factors in the body. This is shown in part of the following experiments.

[0113] Detection of inflammatory cytokines (IL4, TNF-α, IL10 and IFN-γ, etc.) and expression changes of the important protein hs-CRP during the whole process of AS:

[0114] Detection of inflammatory cytokines, etc.:

[0115] Experimental reagents: monkey interleukin 4 (IL4) enzyme-linked immunosorbent assay kit and monkey tumor necrosis factor (TNF-α) detection kit were from Wuhan Elabscience; monkey interferon (IFN-γ) enzyme-linked immunosorbent assay kit was from Wuhan Huamei Bioengineering Co., Ltd. (CUSABIO); monkey interleukin 10 (IF10) was detected using iodine [125I] interleukin-10 interleukin radioimmunoassay kit, and the kit was from Beijing North Biotechnology Institute. Other conventional reagents were domestically produced AR grade.

[0116] According to the detailed methods and steps of IL4 and TNF-α detection kit:

[0117] Preparation before testing: ① Take out the required strips from the aluminum foil bag after equilibration at room temperature for 30 minutes, seal the remaining strips with a ziplock bag and put them back in the refrigerator at 4 degrees. ② Dilute the concentrated washing solution with double distilled water (1:25). Return the unused ones to 4°C. The concentrated washing solution taken out of the refrigerator may have crystals, which is a normal phenomenon. You can use a 40°C water bath to heat the crystals to completely dissolve them before preparing the washing solution (the heating temperature should not exceed 50°C, and the washing solution should be at room temperature when used). Use it on the same day. ③ Standard: Centrifuge at 10000×g for 1min, add 1.0mL of standard & sample diluent to the freeze-dried standard variety, tighten the tube cap, let it stand for 10min, turn it upside down several times, and after it is fully dissolved, gently mix it with a pipette. Then make multiple dilutions as needed (Note: Do not make multiple dilutions directly in the reaction tube). The sample diluent is directly used as the blank well 0pg / mL. (Note: The concentration gradient of IL-4 (monkey) standard is: 1000pg / mL, 500pg / mL, 250pg / mL, 125pg / mL, 62.5pg / mL, 31.25pg / mL, 15.63pg / mL, 0pg / mL. The concentration gradient of TNF-α (monkey) standard is: 2000pg / mL, 1000pg / mL, 500pg / mL, 250pg / mL, 125pg / mL, 62.5pg / mL, 31.25pg / mL, 0pg / mL). ④ Biotinylated antibody working solution: Calculate the amount required for the experiment (100ul / well) before the experiment. The actual preparation should be 100-200ul more. 15min before use, dilute the concentrated biotinylated antibody (1:100) with biotinylated antibody diluent to the working concentration and use it on the same day. ⑤ Enzyme conjugate working solution: Calculate the amount required for the experiment before the experiment (100ul / well), and prepare 100-200ul more. 15 minutes before use, dilute the concentrated HRP enzyme conjugate (1:100) with enzyme conjugate diluent to the working concentration and use it on the same day.

[0118] Washing method: Manual plate washing: shake off the liquid in the wells, pat dry on clean absorbent paper, add 350ul of washing solution to each well, soak for 1-2 minutes, absorb (do not touch the plate wall) or shake off the liquid in the ELISA plate, and pat dry on thick absorbent paper.

[0119] Operation steps: ① Before the experiment begins, all reagents should be balanced to room temperature; when preparing reagents or samples, they must be fully mixed. And try to avoid foaming. ② Sample addition: set up blank wells, standard wells, and sample wells. Add 100ul of sample diluent to the blank well, and add 100ul of standard or sample to be tested to the remaining wells. Be careful not to have bubbles. When adding samples, add the samples to the bottom of the ELISA plate, try not to touch the wall of the well, and gently shake to mix. Cover the ELISA plate with a film and incubate at 37℃ for 90min. ③ Discard the liquid, spin dry, do not wash, add 100ul of biotinylated antibody working solution to each well (prepared within 15min before use), cover the ELISA plate with a film, and incubate at 37℃ for 1 hour. ④ Discard the liquid in the well, spin dry, wash the plate three times, soak for 1-2min each time, about 350ul / well, spin dry and tap the liquid in the well on absorbent paper. ⑤ Add 100ul of enzyme conjugate working solution (prepared within 15 minutes before use) to each well. Add a film. Incubate at 37℃ for 30min. Discard the liquid in the well, spin dry, and wash the plate 5 times. The method is the same as step 3. ⑥ Add 90ul of substrate solution (TMB) to each well, add a film to the ELISA plate and incubate at 37℃ in the dark for about 15min (shorten or extend as appropriate according to the actual color development, but not more than 30min. When a clear gradient appears in the standard well, it can be terminated). ⑦ Add 50ul of stop solution to each well to terminate the reaction. At this time, the blue color immediately turns yellow. The order of adding the stop solution should be as similar as possible to the order of adding the substrate solution. ⑧ Immediately use an ELISA reader to measure the optical density (OD) value of each well at a wavelength of 450nm. The power of the ELISA reader should be turned on in advance, the instrument should be preheated, and the detection program should be set. ⑨ After the experiment is completed, the unused reagents should be returned to the refrigerator for storage at the specified storage temperature.

[0120] Statistical method of experimental results: With the concentration of the standard as the horizontal axis and the OD value as the vertical axis, a standard curve is drawn. The corresponding concentration is found from the standard curve according to the OD value of the sample; then multiplied by the dilution multiple; or the linear regression equation of the standard curve is calculated using the concentration of the standard and the OD value, and the OD value of the sample is substituted into the equation to calculate the concentration of the sample, and then multiplied by the dilution multiple to obtain the actual concentration of the sample. Experimental data and quantitative data are described by arithmetic mean (and geometric mean) ± standard deviation (±SD), the mean comparison between two groups of samples is performed by independent sample t test (and variance homogeneity test), the mean comparison between more than two groups is performed by one-way analysis of variance, and the SNK-q test is used for pairwise comparison between groups; the positive rate is compared by x2 test, and the correlation analysis is performed by Pearson correlation analysis, with the test level α = 0.05.

[0121] Expression changes of anti-inflammatory factors IL4 and IL10:

[0122] Changes in IL4 expression (see Fig.14): The IL-4 concentration of the H-6X group was lower than that of the PBS group before immunization, and the content increased after immunization and gradually exceeded that of the PBS group. Although there was no obvious difference, it can be seen that the IL-4 level increased overall after immunization. And in the last test, it was significantly higher than that of the PBS group.

[0123] The changing trend of IL-10 (see Fig.15 ): There was no significant difference in the initial stage. At the 4th test (the second time after immunization), the average IL-10 content in the H-6X immunization group was 62.18±21.42ng / ml, while that in the PBS group was 32.02±11.82ng / ml. Compared with the PBS group, the IL-10 content in the H-6X immunization group increased by 94.19%, and the IL-10 content was nearly 1 times higher than that in the PBS group, which was significantly different (P<0.05).

[0124] Changes in proinflammatory cytokines TNF-α and IFN-γ:

[0125] Changes in TNF-α expression (see Fig.16 ): At the third test (the first time after immunization), the average TNF-α content in the H-6X immunization group was 50.42±9.65g / ml, while that in the PBS group was 38.41±4.37g / ml. Compared with the PBS group, the TG content in the H-6X immunization group increased by 31.27%, which was significantly different (P<0.05). It is possible that the initial immunization with foreign proteins causes adaptive changes in the body, resulting in a large amount of TNF-α expression in the body in a short period of time. As time goes by, in the later stage of immunization, the TNF-α level in the drug administration group gradually decreases, and basically returns to the same level as the PBS group in the later stage. The decrease in the control ratio after immunization is not obvious, which is related to the insufficient immunogenicity of the epitope, the dosage, or the number of immunizations.

[0126] Changes in IFN-γ expression (see Fig.17 ): At the third detection (the first time after immunization), the average IFN-γ content in the H-6X immunization group was 61.06±13.43pg / ml, while that in the PBS group was 92.57±11.71pg / ml. Compared with the PBS group, the IFN-γ content in the H-6X immunization group decreased by 34.04%, which was a very significant difference (P<0.01).

[0127] HSP65 contains a variety of cell epitopes that can activate different T cell clones, produce TH1 effector inflammatory responses or TH2 effector inflammatory responses. The body's susceptibility to autoimmune diseases depends largely on the balance between different T cell clones, which is regulated by the immune network. Therefore, the experiment can choose to induce the immune response from TH1 to TH2, increase the secretion of TH2 anti-inflammatory cytokines such as IL-4 and IL-10, and inhibit the secretion of TH1 cytokines such as α and IFN-γ.

[0128] IL acts on lymphocytes, macrophages or other cells in the body's inflammatory response, and participates in part or all of the inflammatory response. It plays an important role in immune activation, immune chemotaxis, immune response, inflammation amplification or inflammation suppression. Most ILs play an immunoenhancing role in immune responses, and only a few ILs have immunosuppressive effects, of which IL4 and IL10 are more typical. Many studies have shown that they have different changes in infectious inflammation and autoimmune inflammation. IL-4 and IL10, as anti-inflammatory factors, are mainly produced by Th2 cells, participate in the entire process of inflammatory response, and affect the development and outcome of inflammation. In the present invention, after immunization with H-6X, the expression of the two anti-inflammatory factors increased to varying degrees, and IL10 was more obvious. In the middle and late stages of immunization, the expression increased by 94.19% compared with the control group, which was nearly doubled, and was still higher than the PBS immunization control group in the later stages of the experiment.

[0129] As for the pro-inflammatory factors TNF-α and IFN-γ, they showed a downward trend throughout the immune induction process. The performance of IFN-γ was more obvious, and it was significantly reduced compared with the control group in a short period of time after immunization (P<0.05), and it was still lower than the PBS group until the end of the experiment. TNF-α decreased compared with the control group in the middle and late stages of immunization. But it increased again in the later stage. This may be due to insufficient immunogenicity, immunization dose and number of times, resulting in the inability to sustain the immune effect.

[0130] Hyperlipidemia is also an autoinflammatory disease, which is related to a certain degree of imbalance of pro-inflammatory and anti-inflammatory factors. In the present invention, immunization based on the epitope selected by HSP65 can show a certain immunotherapy effect, with obvious reduction of triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C), which may be caused by the drift of TH1 to TH2 cells in the body. Thereby reducing the secretion of pro-inflammatory factors, increasing the secretion of anti-inflammatory factors, making the pro-inflammatory and anti-inflammatory cytokines tend to develop in a balanced manner to a certain extent, achieving the lipid-lowering effect from the perspective of controlling inflammation.

[0131] Based on the above research work, it is believed that the 6 epitope combination peptides do have certain lipid-regulating and anti-inflammatory effects, and no obvious side effects on its behavior and tissues and organs were found during the research. This multi-epitope combination peptide can be used as a candidate biopharmaceutical for lipid regulation and lipid-lowering through optimized design.

[0132] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Use of a polypeptide composition having lipid-lowering effect in the preparation of lipid-lowering drugs, It is characterized in that The polypeptide composition is composed of six peptide epitopes based on heat shock protein, which are coupled with the immune carrier protein-keyhole limpet hemocyanin respectively and then mixed; The 6 peptide epitopes are: CV14, the amino acid sequence is shown in SEQ ID NO: 1; CL14, the amino acid sequence is shown in SEQ ID NO: 2; CE19, the amino acid sequence is shown in SEQ ID NO: 3; CD17, amino acid sequence as shown in SEQ ID NO: 4; CQ19, the amino acid sequence is shown in SEQ ID NO: 5; CL26, the amino acid sequence is shown in SEQ ID NO:

6.

2. The use according to claim 1, It is characterized in that The method for coupling the six peptide epitopes with the immune carrier protein-keyhole limpet hemocyanin comprises the following steps: 1) Activating the immune carrier protein, keyhole limpet hemocyanin, with SMCC cross-linking agent and dialyzing for 24 hours for later use; 2) coupling the activated immune carrier protein, keyhole limpet hemocyanin, with the six peptide epitopes at a mass ratio of 1:1 for 2 hours; 3) The coupled product was dialyzed for 24 hours for later use.

3. The use according to claim 1, It is characterized in that The mixing is uniform mixing.

Citation Information

Patent Citations

  • Polyepitope tuberculosis gene vaccine and its prepn process

    CN101088559A

  • Anti-atherosis epitope composition, preparation method and uses thereof

    CN101429239A

  • Complete antigen of AG22 polypeptide, preparation method and antibody thereof

    CN103524629A

  • Preparation method of novel coronavirus nucleocapsid protein monoclonal antibody

    CN112111007A